Wuxi Biologic to Acquire Bayer’s Production Facility in Germany

Wuxi Biologic; Acquire; Bayer; Production Facility; Germany


  • Wuxi Biologic to take over operations of Bayer’s manufacturing plants in Leverkusen, Germany and purchase its associated equipment in combination with a long-term lease contract for the building
  • As per the manufacturing agreement to be negotiated, Wuxi operated plant shall serve as a backup site for manufacturing Kovaltry, an antihemophilic factor (recombinant) while Bayer’s facility in California, US will remain the major site for manufacturing and filing of it
  • Kovaltry is used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in patients with hemophilia A and controls bleeding in hemophilic patients

Click here ­to­ read full press release/ article | Ref: Bayer | Image: The Pharma Letter